RedHill Biopharma announces first patient dosed in U.S. Phase 2/3 COVID-19 outpatient study with RHB-107
RHB-107 is a novel serine protease inhibitor targeting human cell factors involved in viral entry, and is therefore expected to be effective against emerging viral variants with mutations in the spike protein